February 19, 2025, Charlottesville VA: Contraline has published peer-reviewed data in the journal, Contraception, detailing the development of ADAM™, a novel injectable two-component hydrogel designed to offer a safe, long-lasting, and non-permanent solution for male contraception.

The study highlights preclinical findings that showcase the hydrogel’s biocompatibility and tunable mechanical properties, setting it apart from existing vas-occlusive technologies.

Key findings from the study include:

• The hydrogel's selective permeability with a pore size range of 10-20 nm, which effectively prevents sperm passage while allowing fluid and small molecules to diffuse.
• Its mechanical properties, which enable easy injection into the vas deferens with minimal force, forming a stable, viscoelastic material within 30 seconds that withstands ejaculatory pressures.
• The hydrogel was shown to be non-cytotoxic, non-irritating, non-sensitizing, and non-genotoxic, emphasizing its safety profile.
• A two-year in vivo study in a canine model revealed minimal tissue response following implantation, with no adverse effects, further supporting the hydrogel’s long-term safety and functionality.

“We are pleased to share our research in Contraception, a journal with a longstanding history in male contraception, including seminal publications on vas-occlusive approaches dating back to 1979. This manuscript details the preclinical development of ADAM™, the first injectable PEG hydrogel designed for non-permanent vas-occlusive contraception. We are proud to contribute to this field and advance the development of innovative contraceptive technologies,” said Dr. Nic Matsumoto, Director of Research at Contraline.

"These results culminated from years of dedicated research developing, optimizing, and testing ADAM™ in various preclinical models. ADAM™ has the potential to be the first product that offers men long-lasting, non-hormonal, and reversible contraception. We believe it will fill a crucial gap in the options available for male reproductive health," said Kevin Eisenfrats, Co-Founder and CEO of Contraline.

The ADAM™ device is currently being studied in a First-in-Human trial in Australia (NCT05134428).

Disclaimer ADAM™: ADAM™ is an investigational device and is not yet authorized by the U.S. Food and Drug Administration (FDA) or any other regulatory authority worldwide. As such, ADAM™ is not available for commercial use at this time and it is currently available only for investigational use in approved clinical trials.

About Contraline: Contraline, Inc. is a venture-backed, clinical-stage, biotechnology company focused on innovation in reproductive health. The company’s mission is to develop novel male contraceptives that are safe, effective, appealing, and reversible. Visit www.contraline.com